BRD4-IN-11
BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2) ) . BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; c-Myc; Epigenetic Reader Domain; Phosphatase
Related Pathways
Apoptosis; Epigenetics; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
CC1=NN=C2[C@@H](N=C(C3=C(N12)SC(C)=C3C)C4=CC=C(C=C4)Cl)CC(OC5=CC=C(C=C5)OCCCCCCOC6=CC=C(C=C6)C7=CC(SS7)=O)=O
Molecular Formula
C40H37ClN4O5S3
Molecular Weight
785.39
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
